PD-L1 IHC 22C3 pharmDx can help identify gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA
PD-L1 is a proven biomarker for patient response to KEYTRUDA in certain tumors
Despite decreasing incidence and an increasing number of treatment options, gastric cancer continues to be a leading cause of cancer-related mortality worldwide
IHC testing for PD-L1 expression levels enables identification of patients most likely to benefit from anti-PD-1 monotherapy—in KEYNOTE-059, a KEYTRUDA clinical trial, 58% of patients with gastric or GEJ adenocarcinoma had tumors that exhibited PD-L1 expression
PD-L1 testing should be an integral part of patient care from day ONE
Because patients with gastric or GEJ cancer have poor prognosis, it is critical to assess their PD-L1 expression status upon diagnosis
Most gastric cancer patients present at an advanced stage and are treated with upfront, systemic chemotherapy. Patients may initially respond to treatment, but many of them relapse over time, with durations of response being as short as a few months
Therefore, it is important to test for PD-L1 upon diagnosis to better inform long-term patient management and treatment
PD-L1 IHC 22C3 pharmDx Gastric or GEJ Adenocarcinoma Interpretation Training ProgramGet the training that may help you accurately evaluate and score PD-L1 expression in patients with gastric or GEJ adenocarcinoma
PD-L1 IHC 22C3 pharmDx Gastric or GEJ Adenocarcinoma Interpretation ManualRefer to the Gastric or GEJ Adenocarcinoma Interpretation Manual to review validated scoring guidelines that can help identify gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA
Online Atlas of Stains for Gastric or GEJ adenocarcinoma: PD-L1 IHC 22C3 pharmDxUse the Online Atlas of Stains for Gastric or GEJ Adenocarcinoma to increase your familiarity with PD-L1 staining in gastric or GEJ adenocarcinoma specimens
Trust the ONE PD-L1 test FDA-approved to determine PD-L1 expression in patients with gastric or GEJ adenocarcinoma
Proven in KEYNOTE-059, a KEYTRUDA clinical trial, for PD-L1 results in gastric or GEJ adenocarcinoma that you can rely on
PD-L1 IHC 22C3 pharmDx was used to assess PD-L1 expression in patients treated with KEYTRUDA in the KEYNOTE-059 trial
Fifty-eight percent of patients had tumors that expressed PD-L1 with a Combined Positive Score (CPS)* of greater than or equal to 1
After failing 2 or more prior therapies, gastric or GEJ adenocarcinoma patients with PD-L1 expression and microsatellite stable tumor status (or unknown) demonstrated an overall response rate of 13.3%
PD-L1 Prevalence in Patients with Gastric or GEJ Adenocarcinoma Enrolled in KEYNOTE-059
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
References:1. PD-L1 IHC 22C3 pharmDx [package insert]. Carpinteria, CA: Dako, Agilent Pathology Solutions; 2018.
2. Keytruda [package insert]. Kenilworth, NJ: Merck & Co., Inc.; 2018.
3. American Cancer Society. Global cancer facts & figures 3rd edition. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf. Published 2015. Accessed September 27, 2017.
4. Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol. 2015;21(41):11621-11635.
5. Ji SH, Lim DH, Yi SY, et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2009;9:110.
For countries outside of the United States, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.